These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16731537)

  • 1. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
    Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
    Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma.
    Rey J; Wickenhauser S; Ivanov V; Coso D; Gastaut JA; Bouabdallah R
    J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):210. PubMed ID: 18482321
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab in cutaneous B-cell lymphoma: a report of two cases.
    Sabroe RA; Child FJ; Woolford AJ; Spittle MF; Russell-Jones R
    Br J Dermatol; 2000 Jul; 143(1):157-61. PubMed ID: 10886152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
    Kollmar O; Becker S; Schilling MK; Maurer CA
    Transplantation; 2002 Feb; 73(4):669-70. PubMed ID: 11889454
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
    Kennedy GA; Blum R; McCormack C; Prince HM
    Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
    Heinzerling L; Dummer R; Kempf W; Schmid MH; Burg G
    Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
    Hao LC; Zhang LZ
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
    Jabr FI
    Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
    Clarke LE; Bayerl MG; Ehmann WC; Helm KF
    J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of cutaneous intravascular lymphoma with rituximab.
    Han K; Haley JC; Carlson K; Pinter-Brown L; Soriano T
    Cutis; 2003 Aug; 72(2):137-40. PubMed ID: 12953938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
    Massengale WT; McBurney E; Gurtler J
    J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.
    Dillman RO
    J Clin Oncol; 2002 Aug; 20(16):3545-57. PubMed ID: 12177115
    [No Abstract]   [Full Text] [Related]  

  • 16. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
    Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG
    J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cutaneous marginal zone B-cell lymphoma treated with rituximab].
    Pedraz J; Delgado Y; Aragüés M; Fraga J; García-Díez A; Fernández-Herrera J
    Actas Dermosifiliogr; 2005 Nov; 96(9):593-7. PubMed ID: 16476304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-related urticarial reaction overlying primary cutaneous follicle centre lymphoma: histological appearance and pathophysiological hypotheses.
    Ingen-Housz-Oro S; Ortonne N; Chosidow O
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):976-8. PubMed ID: 24206369
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
    Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
    Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.